Skip to main content

DPP4 inhibitor-induced polyarthritis: a report of three cases

Abstract

Dipeptidyl peptidase-4 (DPP4) inhibitors are a novel therapy widespread used in type 2 diabetes mellitus. We describe 3 cases of polyarthritis which delay of appearance strongly suggests a link with DPP4 inhibitors. Three patients presented with bilateral, symmetrical, seronegative polyarthritis after introduction of DPP4 inhibitors (sitagliptine (n = 2) and vildagliptine (n = 1)). Two patients also developed xerostomia and xerostomia, and laboratory test results showed normal values of CRP and erythrocyte sedimentation rate. Joints X-rays were normal. One patient was diagnosed with primary Sjögren’s syndrome and treated with hydroxychloroquine, methotrexate and prednisone, with a poor efficacy. When sitagliptine was stopped, all symptoms disappeared, leading to methotrexate and prednisone discontinuation within a month. There were no immunological abnormalities in the 2 other patients, but a chronic viral hepatitis B was found in one patient. Eventually, discontinuation of DPP4 inhibitors led to resolution of symptoms in 1 and 3 weeks for both patients. DPP4 inhibitors seemed to trigger bilateral, non-erosive, seronegative polyarthritis in our 3 patients. DPP4, also known as CD26, is expressed on many cells including lymphocytes and fibroblasts, and its inhibition may lead to immunomodulating effect as suggested by clinical and in vitro studies.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Stulc T, Sedo A (2010) Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract 88:125–131

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Yan S, Marguet D, Dobers J, Reutter W, Fan H (2003) Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 33:1519–1527

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE (2006) Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632–2637

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9:194–205

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H (2006) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49:2564–2571

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Yamauchi K, Sato Y, Yamashita K et al (2012) RS3PE in association with dipeptidyl peptidase-4 inhibitor: report of two cases. Diabetes Care 35:e7

    PubMed  Article  Google Scholar 

  8. 8.

    Ospelt C, Mertens JC, Jungel A et al (2010) Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 62:1224–1235

    CAS  PubMed  Article  Google Scholar 

Download references

Conflict of interest

No potential conflicts of interest relevant to this article were reported.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jean-Emmanuel Kahn.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Crickx, E., Marroun, I., Veyrie, C. et al. DPP4 inhibitor-induced polyarthritis: a report of three cases. Rheumatol Int 34, 291–292 (2014). https://doi.org/10.1007/s00296-013-2710-7

Download citation

Keywords

  • DPP4 inhibitors
  • Drug-induced polyarthritis
  • Type 2 diabetes mellitus